As human lifespan extends, improved healthspan involves resilience to age-related diseases and functional decline. Our group is utilizing Olink proteomics in a North American longitudinal clinical cohort to develop blood-based signatures of long-term steady-state resilience across multiple age-related domains including cognitive function, physical function, sensory function, and multimorbidity.
Using the UK Biobank our objectives are:
1. We aim to validate our existing proteomic signatures of long-term resilience using the UK Biobank Olink proteomic dataset. Specifically, we will examine the predictive accuracy of our current proteomic signatures of resilience to identify older-adult participants whose cognitive, physical, and sensory function and multimorbidty does not decline between the two assessments.
2. We aim to apply our established computational approach to the UK Biobank data to identify novel proteomic predictors of short-term dynamic resilience among older adults. Using UK Biobank record-level hospital inpatient admission data, we will characterize dynamic resilience using re-admission and mortality outcomes.